Patent Positions Metabolon As The Leading Metabolomics Provider For Discovery And Therapeutic Solutions

RESEARCH TRIANGLE PARK, NC (March 23, 2006) – Metabolon, Inc., a leader in the identification of novel biomarkers that reveal disease processes and drive drug development, today announced the issuance of United States Patent 7,005,255, titled “Methods for drug discovery, disease treatment, and diagnosis using metabolomics.” The patent broadly covers metabolomic methods used to identify the molecular profiles, or biomarkers, seen in patients with amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease).

Back to news